HALEON Haleon Pakistan share price
Haleon Pakistan in one paragraph
As of 20 Nov 2026, the Haleon Pakistan (HALEON) share price is Rs 687.73 (0.00% on the day). Over the last year it has moved −16.25%. Its market capitalisation is about Rs 80.5B. The trailing dividend yield is 3.64%. PSX lists it as Shariah-compliant. Haleon Pakistan is in the Pharmaceuticals sector, and is a KSE-100 member. Its last cash dividend was Rs 10.00 a share, ex-date 7 Sep 2026.
Close · 20 Nov 2026 · Pakistan Stock Exchange · Vol 7.3K live
−0.01 (0.00%)
52-week low650.00
52-week high1,010.00
Before 31 Jan 2023 this company traded as GSKCH, GlaxoSmithKline Consumer Healthcare. Sessions before that date were recorded under GSKCH. The exchange's filing: “Approval of Company Name Change - Haleon Pakistan Limited”.
DEx-dividend day: the price falls by about the payoutRResults filedNo marks before 16 Oct 2024: SuperX's dated record of dividends and results starts there.
HALEONKSE-100, price onlyBoth: the change in percent since the first close drawn.
A period starts at the last close on or before the same date one week, one, three or six months, or one, three or five years earlier, and ends at the latest close drawn. The year to date starts at the last close of the previous year.
- 1 week
- −1.34%
- 1 month
- +2.51%
- 3 months
- −4.64%
- 6 months
- −7.19%
- Year to date
- −17.47%
- 1 year
- −16.25%
- 3 years
- +324.29%
- 5 years
- +169.70%
- Since Mar 2017
- +957.23%
Daily closes from the Pakistan Stock Exchange, to 20 Nov 2026.
- Last price
- Rs 687.73
- 20 Nov 2026
- Change on the day
- 0.00%
- −Rs 0.01
- Market cap
Market cap
What the whole company costs at today's price.
How it's worked out
Share price multiplied by every share in issue.
How to read it
It is the company's size, not its value. A big number does not mean the price is high against earnings, and a small one does not mean it is low — that is what the ratios below are for.
- Rs 80.5B
- as of 20 Nov 2026
- Price per rupee earned
Price per rupee earned
Rupees you pay for each rupee the company earned last year.
How it's worked out
Share price divided by earnings per share over the last twelve reported months.
How to read it
Lower only means something against something — the same company's history, its sector, or the market. On its own this ratio says very little, and it is blank when a company lost money.
- 12.35×
- price-to-earnings · unconsolidated, the last twelve months (PSX screener)
- Dividend yield
Dividend yield
Cash paid out over the last year as a percentage of today's price.
How it's worked out
Dividends per share over twelve months divided by the share price.
How to read it
A very high yield is often a warning, not a gift: it usually means the price fell. Check the payout ratio next to see whether earnings actually cover it.
- 3.64%
- Rs 25.00/sh last 12m ÷ Rs 687.73
- Earnings per share
- Rs 54.45
- the year to 31 Dec 2025
- 52-week range
- 650.00 – 1,010.00
- the price is at 11% of the range
- Day range
- 683.00 – 689.99
- prev close 687.74
- Volume
- 7.3K
- shares, this session
- Avg volume (30d)
Average volume
Shares changing hands on a typical day.
How it's worked out
The mean daily volume over thirty sessions.
How to read it
Shares, not rupees — a million shares of a Rs 3 stock is a small market. "Traded per session" is the version in money.
- 28.7K
9 more figures
- Beta vs KSE-100
Beta
How hard it swings when the market swings.
How it's worked out
The slope of this stock's daily returns against the KSE-100's, over a year of sessions.
How to read it
1.0 moves with the market, 1.5 exaggerates it by half, below 1 is steadier. It says nothing about direction, only about size.
- 0.86
- 1 year of daily closes
- Book value / share
- Rs 126.41
- accounts to 31 Dec 2025
- Shares outstanding
- 117M
- Free float
Free float
The shares that can actually be bought and sold.
How it's worked out
Total shares minus the blocks held by sponsors, the government and other locked-in holders, as the exchange reports them.
How to read it
The float, not the market cap, is what sets how easily a real position can be built or unwound.
- 15.7M
- 13.4% of shares
- Last dividend
- Rs 10.00
- ex-date 7 Sep 2026
- Last results filed
- 29 Oct 2026
- Sector
- Pharmaceuticals
- Index member
- All-Share, KMI All-Share, KSE-100
- Shariah
- Compliant
Figures as of 20 Nov 2026.
What changed for HALEON
Latest · 4 items · to 20 Nov · You follow HALEON
- 20 NovClosed 687.73, 0.00%. Volume 7,304, 0.3 times the average of the 30 sessions before it, 27,781. New
- 29 OctQuarter ended 30 Sep 2026: earnings per share Rs 13.05, sales Rs 10.0 bn, down 5.4% on the same quarter a year before. All results New
- 5 NovTrend read changed to sideways: above the 50-day average, below the 200-day; roughly flat over 3 months (−5.8%). New
- NextAnnual results (to 31 Dec 2026) expected 7 Feb 2027 – 31 Mar 2027, a projection. An estimate from the dates of the last 4 filings.
Closes and notices: PSX. Trend read: SuperX, from daily closes. Volume: against the average of the 30 sessions before the last. Next results: an estimate from the dates of the last 4 filings. Not advice.
What SuperX wrote about HALEON
SuperX holds no shares in Haleon Pakistan.
The price closed at 687.73 PKR on 20 Nov, unchanged. The whole PHARMACEUTICALS sector had a median move of 0.0%. The price did not move today.
Next annual results cover the period ending 31 Dec. Last year the company filed them on 3 Mar.
Q3 2026 EPS fell 5.43% to 13.05 PKR from 13.8 PKR a year ago. Profit after tax fell 5.42%.
Written by SuperX’s analyst desk from SuperX’s own figures, from the close of 20 Nov 2026. Each number was checked against those figures. Not advice.
01Returns1 year −16.25%
HALEON in figures
As of 20 Nov 2026. Each figure states its period, its basis and its source. Not advice.
Return over time
Returns to the price at 16:45 on 20 Nov 2026. The sector median runs to the close of 20 Nov 2026, over 14 companies.
Change in price since 21 Nov 2025, weekly closes, each line starting at zero
This stockKSE-100, price onlySector median
Method
Every line starts at 0% on 21 Nov 2025. The index line is the KSE-100 price index (KSE100PR), which leaves dividends out, so both lines are price only. The table below gives the return with dividends. Source: PSX closes and the KSE100PR index.Return with dividends over each window, against the KSE-100
This stockKSE-100
Up to one yearone scale, -14.5% to +8.9%
1 month
3 months
6 months
Year to date
1 year
Three and five yearsone scale, 0.0% to +361.3%
3 years
| Over | Price only | With dividends | KSE-100 | Sector median |
|---|---|---|---|---|
| 1 monthfrom the close of 20 Oct 2026, Rs 670.90 | +2.51% | +2.51% | +7.41% | +4.09% (10 companies) |
| 3 monthsfrom the close of 20 Aug 2026, Rs 721.16 | −4.64% | −3.25%dividends Rs 10.00 | +0.45% | −3.06% (10 companies) |
| 6 monthsfrom the close of 20 May 2026, Rs 740.98 | −7.19% | −5.84%dividends Rs 10.00 | +7.61% | −1.83% (10 companies) |
| Since 1 Januaryfrom the close of 31 Dec 2025, Rs 833.32 | −17.47% | −14.47%dividends Rs 25.00 | +1.91% | −10.71% (10 companies) |
| 1 yearfrom the close of 20 Nov 2025, Rs 821.15 | −16.25% | −13.20%dividends Rs 25.00 | +8.87% | −14.10% (10 companies) |
| 3 yearsfrom the close of 20 Nov 2023, Rs 162.09 | +324.29% | +361.31%dividends Rs 60.00 | +210.77% | +130.02% (9 companies) |
Price only: closes adjusted for bonus and rights issues, to the latest price. With dividends: adds cash dividends, not reinvested. The KSE-100 figure reinvests dividends. Source: PSX closes and payout notices.
02Value12.35× per rupee earned
Key figures against the sector
Against sector and market
This stockSector medianMarket median
Price per rupee earned
Dividend yield
Net profit share of salesabove 76% of 411 companies
Sales growth a year, 3 yearsabove 73% of 295 companies
Earnings per share growth, 3 yearsabove 97% of 234 companies
Gross profit share of salesabove 88% of 367 companies
| Price per rupee earned | 12.35× | sector median 12.32× (12 companies) · level with the sector median · above 6 of 12 sector companiesunconsolidated, the last twelve months (PSX screener) |
| Dividend yield | 3.64% | 7 of 14 sector companies pay a dividend · median over payers only: 5.12% (7 companies) · 28.9% below the sector median · above 2 of 7 sector companiesCash dividends of the last 12 months over the price |
| Net profit as a share of sales | 14.78% | sector median 9.41% (13 companies) · 57.1% above the sector median · above 11 of 13 sector companiesLatest filed year, to 31 Dec 2025, company accounts |
| Sales growth a year, over 3 years | 16.15% | sector median 16.35% (11 companies) · level with the sector median · above 5 of 11 sector companiesFiled sales, year to 31 Dec 2022 to year to 31 Dec 2025, company accounts |
| Move with the KSE-100 (beta), 1 year | 0.86 | sector median 1.06 (14 companies) · 18.2% below the sector median · above 5 of 14 sector companiesDaily price changes over the year to 20 Nov 2026, against the KSE-100 |
| Return over 1 year, with dividends | -13.20% | sector median -10.21% (14 companies) · 29.3% below the sector median · above 5 of 14 sector companiesPrice change over one year plus cash dividends, not reinvested |
| Earnings per share growth a year, over 3 years | 169.56% | sector median 21.11% (9 companies) · 8.0 times the sector median · above 9 of 9 sector companiesFiled earnings per share over three years, on today’s share count, company accounts |
| Gross profit as a share of sales | 39.09% | Latest filed year, company accounts |
A figure is called above or below the sector median when the gap is more than 10%.
Compared with the 14 other companies in its PSX sector, Pharmaceuticals. A sector median is left out when no other company in the sector has the figure.
The same ratio on other definitions
HALEON earnings per share: Rs 54.45 · unconsolidated · the year to 31 Dec 2025 · PSX company page
Price per rupee earned, our own: 12.63 (687.73 on 20 Nov 2026 over 54.45, unconsolidated, the year to 31 Dec 2025)
The valuation in context
How does HALEON’s valuation compare with its sector?
From filed accounts and HALEON's price history · as of 20 Nov 2026
One ratio on its own says little. These put HALEON's valuation next to its sector and the market, its dividend next to its earnings, its quoted price next to how much of it actually trades, and its return next to the risk taken to earn it.
Valuation in context
- Earnings yield
Earnings yield
What the business earns on its price, so it lines up with a savings rate.
How it's worked out
Earnings per share divided by the share price — the price-to-earnings ratio turned over.
How to read it
If a company earns 17% against its price and a T-bill pays 12%, you can finally compare the two. It is what the business earns, not what it pays you — the dividend yield is the cash that reaches your account.
- 8.10%
- Price to sales
Price to sales
What you pay for each rupee of revenue.
How it's worked out
Market cap divided by the latest reported annual sales.
How to read it
Useful where earnings are negative or lumpy and a price-to-earnings ratio says nothing. It ignores costs entirely, so a low number does not mean a good business.
- 1.87×
- Price, earnings and growth together
Price, earnings and growth together
The price per rupee earned, measured against how fast earnings are growing.
How it's worked out
The price-to-earnings ratio divided by the three-year growth rate of earnings per share.
How to read it
Under 1 is the old rule of thumb for a multiple that growth justifies. Blank when earnings are shrinking, because the ratio flips sign and stops meaning anything.
- 0.07
- vs the KSE-100's own multiple
vs the KSE-100's own multiple
Whether a rupee of this company's earnings costs more or less than the market's.
How it's worked out
Its price-to-earnings ratio against the KSE-100's, which we compute as the total market cap of the index over the total earnings of its members.
How to read it
−30% means it trades thirty percent below the market's multiple. Below the market is a question, not an answer: often the market is right about why.
- +55%
- vs KSE-100, one year
vs KSE-100, one year
How far ahead of or behind the market it finished.
How it's worked out
Its one-year return minus the KSE-100's, in percentage points.
How to read it
"Up 12%" means one thing when the index rose 20% and another when it fell. Unlike alpha, this ignores how much market risk was carried to get there.
- -18.6 pts
It costs less for each rupee earned than 50% of the pharmaceuticals companies with reported earnings, and it yields more than 21% of them.
Income & quality
- Dividend per share, 12 months
Dividend per share
The actual rupees per share paid out over the last twelve months.
How it's worked out
Every cash dividend with an ex-date in the last year, added up from the exchange's own book-closure notices.
How to read it
Multiply by your shares and that is the cash that reached you, before tax. Bonus shares are not in here — they are not money.
- Rs 25.00
- Cash dividends paid, 12 months
Dividends paid
How many times it paid cash in the last twelve months.
How it's worked out
A count of cash dividends with an ex-date in the last year.
How to read it
Four usually means a quarterly payer, one means an annual one. A steady cadence is worth more to an income investor than a single big number.
- 2
- Payout ratio
Payout ratio
How much of its profit the company hands to shareholders.
How it's worked out
Dividend per share over the last year divided by earnings per share.
How to read it
Above 100% means it paid out more than it earned — possible from reserves for a year, not for five. Low means it is keeping money to reinvest, which is not automatically bad.
- 46%
- Dividend cover
Dividend cover
How many times over the earnings could pay the dividend.
How it's worked out
Earnings per share divided by dividend per share — the payout ratio the other way round.
How to read it
Above 2 is comfortable. Below 1 means the dividend is coming from somewhere other than this year's profit.
- 2.18×
- Net margin
Net margin
How much of every rupee of sales survives to profit.
How it's worked out
Net profit after tax divided by sales, from the annual filing.
How to read it
Compare it only within an industry — a supermarket at 3% can be healthier than a manufacturer at 10%. The direction matters more than the level.
- 14.8%
- Margin, 3-year change
Margin, 3-year change
Whether the business is getting more or less profitable.
How it's worked out
The latest net margin minus the one three years earlier, in percentage points.
How to read it
A widening margin on flat sales is a company with pricing power. A shrinking one is usually costs, competition, or both.
- +13.6 pts
- EPS growth, 3-year
EPS growth, 3-year
How fast profit per share has compounded.
How it's worked out
The annual rate that turns the earnings per share of three years ago into today's.
How to read it
Blank if the company was losing money three years ago — a move from a loss to a profit has no meaningful growth rate, and printing one would be arithmetic pretending to be insight.
- +169.6% a year
- Sales growth, 3-year
Sales growth, 3-year
How fast revenue has compounded.
How it's worked out
The annual rate that turns the sales of three years ago into today's.
How to read it
Read it next to EPS growth. Sales rising faster than profit means the growth is being bought with margin.
- +16.1% a year
It paid out 46% of earnings and kept the rest.
Can you actually trade it
- Median traded per session
Traded per session
The rupees that change hands on a typical day.
How it's worked out
The median of price times volume over the last 60 sessions — the median, so one block trade cannot make a dead stock look busy.
How to read it
This is the number that decides whether the quoted price is a price you can actually get.
- Rs 11.9M
- Sessions to trade Rs 1M
Sessions to trade Rs 1M
How long it would take to trade into or out of a Rs 1,000,000 position.
How it's worked out
Rs 1,000,000 divided by the median rupees traded a session.
How to read it
Under 0.01 and your order is a rounding error. Above 1 and you are the day's volume — expect to move the price against yourself getting out.
- 0.08
- Untraded sessions, last 60
Untraded sessions
Days in the last 60 when literally nothing traded.
How it's worked out
A count of sessions with zero volume.
How to read it
Any number above zero means there are days you could not have sold at any price. On PSX this is common well outside the KSE-100.
- 0
- Daily volume vs free float
Daily volume vs free float
What share of the tradable stock changes hands on a normal day.
How it's worked out
Average daily volume divided by the free float — the shares not locked up by sponsors.
How to read it
A company can be huge and still barely trade if the family owns 90% of it. This separates size from liquidity.
- 0.20%
- Price impact per Rs 1M traded
Price impact per Rs 1M
How much a Rs 1,000,000 order moves the price on a typical day.
How it's worked out
We take the size of the price move on each day and divide it by the money traded that day, then scale it to a Rs 1,000,000 order. We use the middle value over the last year. Traders call this the Amihud ratio. It is shown in basis points: 100 basis points is 1%, so 0.07 basis points is 0.0007%.
How to read it
A small number means an order of this size barely moves the price. A large number means the price moves a lot when someone buys or sells this much.
- 5 bps
- Implied bid-ask spread
Implied bid-ask spread
The hidden cost of a round trip, estimated from the price series.
How it's worked out
Roll's estimator: prices bounce between bid and ask, and the size of that bounce implies the spread.
How to read it
It is the toll you pay to enter and leave, before any brokerage. Blank when the price is trending rather than bouncing, because then the model does not apply and we would rather say nothing.
- 0.92%
- Float turned over, one year
Float turned over, one year
How many times the tradable stock changed hands in a year.
How it's worked out
A year's volume divided by the free float. Exchanges publish this about themselves; this is the same measure for one company.
How to read it
100% means the entire float turned over once. Single digits mean a register that never moves, whatever the market cap says.
- 84%
- Sessions with a trade, one year
Sessions with a trade
How often it trades at all.
How it's worked out
The share of the last 250 sessions with any volume.
How to read it
Anything below 100% means there were days with no market. Below 90% is more than 25 such days in the last 250 — on each of those days no trade happened at any price, so an order placed that day did not execute.
- 100%
Liquidity is comfortable: a Rs 1,000,000 order is about 8% of a normal session's turnover.
A Rs 1,000,000 ticket nudges the price — about 5 basis points on the median session.
What the risk paid
- Total return, one year
Total return, one year
What a holder actually made, dividends included.
How it's worked out
The price move over twelve months plus every cash dividend paid in that window, counted as received on its ex-date.
How to read it
Every other PSX site quotes the price move alone. On a market yielding what this one does, that understates what holders made by a third or more.
- -13.2%
- — from the price
- -16.2%
- — from dividends
— from dividends
The part of the year's return that arrived as cash.
How it's worked out
Dividends per share over the year divided by the price twelve months ago.
How to read it
The half of the return a price chart cannot show you. For many PSX names it is most of it.
- +3.0%
- Return per unit of risk
Return per unit of risk
How much you were paid for how rough the ride was.
How it's worked out
The one-year return divided by the annualised volatility of the daily moves.
How to read it
Two stocks up 20% are not the same if one did it calmly and the other halved on the way. Deliberately not a Sharpe ratio: quoting a risk-free rate for Pakistan means picking a T-bill tenor and pretending that was your alternative.
- -0.54
- Alpha vs KSE-100, one year
Alpha vs KSE-100
The part of the year's return the market does not explain.
How it's worked out
The stock's return minus its beta times the index's return.
How to read it
A high-beta name rising in a rising market has done nothing clever. This strips that out and leaves what was actually the company's doing.
- -18.3 pts
- Caught of the market's up moves
Caught of the market's up moves
How much of the market's good days this stock catches.
How it's worked out
The stock's total return across the index's up days, divided by the index's own.
How to read it
Above 100 means it rises more than the market does. Read it with down capture — the pair is the whole picture, either half alone flatters.
- 66%
- Caught of its down moves
Caught of its down moves
How much of the market's bad days this stock catches.
How it's worked out
The stock's total return across the index's down days, divided by the index's own.
How to read it
Below 100 means it falls less than the market. Above 100 means it falls further than the market does on the market's bad days, which a headline return usually hides.
- 82%
- Worst day in twenty
Worst day in twenty
The fall to expect on a bad day.
How it's worked out
The fifth-percentile daily return over the last year — the actual distribution, not a bell curve.
How to read it
One session in twenty is at least this bad. It is a normal day at the office, not a crash, and the crash is worse than this by definition.
- −2.7%
- Below its 52-week high
Below its 52-week high
How far under its best price of the year it sits now.
How it's worked out
The 52-week high minus today's price, as a percentage of that high.
How to read it
Different from the biggest drawdown, which is the worst it ever got. This is the hole still to climb out of.
- 31.9% · 207 sessions
It has fallen with the index more than it has risen with it.
Brokers’ price targets
Brokers’ 12-month price targets for HALEON, not SuperX’s
Collected from sell-side research notes. The figures here are the brokers’.
- Lowest target
- Rs 1,097.00
- Average target
- Rs 1,097.00
- Highest target
- Rs 1,097.00
- Analysts
- 1
- EPS this FY
- Rs 59.10
- EPS next FY
- Rs 64.80
Brokers cover 49 PSX companies and rate 47 of them buy, 0 hold and 0 sell. 2 have another rating. The split of ratings for HALEON is not shown: the count of ratings does not match the 1 analysts behind these targets. Targets as of 18 Sep 2026.
A target is one analyst’s estimate of a price twelve months out. SuperX does not check it, score it, or convert it into a view.
Computed value range
Where the middle half of Pharmaceuticals’s price-to-earnings ratios would put the price: Rs 596.23 to Rs 1,012.63. 12 companies, 2 left out (a loss, no ratio, or a ratio over 100). Earnings per share Rs 54.45 for the period to 31 Dec 2025, from company accounts. A method, not advice.
The price of Rs 687.73 on 20 Nov 2026 is inside this range. The middle of the range is Rs 670.82.
Computed value range
Low Rs 596.23Middle Rs 670.82High Rs 1,012.63
The band is the range, the tick is its middle and the arrow is the price. Source: the exchange’s price-to-earnings ratios and filed accounts.
SuperX’s own method, worked out from the exchange’s ratios. It is not a broker’s target and not advice.
03Grades and checks6 checks
Grades, A to F
As of 20 Nov 2026. Each grade ranks HALEON among 408 traded companies (at least Rs 10 m traded on 18 of the last 20 sessions), across the whole market and not only its sector. A: the top 20%. B: 60 to 80. C: 40 to 60. D: 20 to 40. F: the bottom 20%. The figures in a grade count equally.
Grade ranks, 0 to 100
This stockSector median
Method
The letter is the grade. The sector median is over 14 companies. The inputs are listed below.ahead of 28.3% of graded companies · from 3 of 3 figures
- earnings over price: 8.10%, ahead of 36% of companies
- book value over price: 18.38%, ahead of 6% of companies
- dividend yield: 3.64%, ahead of 73% of companies
ahead of 86.4% of graded companies · from 2 of 2 figures
- sales growth, 3 years: 16.15%, ahead of 72% of companies
- earnings per share growth, 3 years: 169.56%, ahead of 98% of companies
ahead of 74.9% of graded companies · from 1 of 2 figures
- net profit as a share of sales: 14.78%, ahead of 75% of companies
ahead of 28.7% of graded companies · from 3 of 3 figures
- return, 90 days: -5.81%, ahead of 48% of companies
- return, 182 days: -9.74%, ahead of 22% of companies
- return, 1 year: -16.25%, ahead of 32% of companies
Each letter shows where the company’s own figures stand among the traded companies on that date. Not advice and not a forecast.
What's good about HALEON, and what isn't
As of 20 Nov 2026
Each line names the test it passed, in the small print under it. Nothing here is scored or ranked.
In its favour
-
The multiple is covered by growth — a PEG of 0.07.
PEG below 1 on three-year earnings growth
-
The dividend is covered 2.2 times by earnings.
Earnings at least twice the dividend
-
Earnings per share compounded 170% a year over three years.
Three-year EPS growth of 15% or more
-
Net margin is 13.6 points wider than three years ago.
Margin up 2 points or more over three years
Against it
-
Trades 55% above the KSE-100's own multiple.
50% or more above the KSE-100's own multiple: its total market value over its members' total earnings
Worth knowing
-
It sits 30% below its highest close of the last 52 weeks (Rs 989.01 on 2026-01-19), 207 sessions ago.
30% or more below the highest close of the last 52 weeks
Not advice, and not a score. Each line describes a figure on this page.
04ResultsBy year and by quarter
Sales, profit and earnings per share, by year
What are HALEON’s sales, profit and earnings per share?
Results, by period end
Earnings per share by financial year, Rs, with the change on the year before
Sales by financial year, Rs billion
Profit margins by financial year
Net profit share of salesGross profit share of sales
| Period | Earnings per share (Rs) | Sales | Net profit as a share of sales | Change in earnings per share on the year before |
|---|---|---|---|---|
| Year to 31 Dec 2025 | 54.45 | Rs 43.1 bn | 14.78% | +39.2% |
| Year to 31 Dec 2024 | 39.11 | Rs 37.2 bn | 12.31% | +359.6% |
| Year to 31 Dec 2023 | 8.51 | Rs 31.6 bn | 3.15% | +206.1% |
| Year to 31 Dec 2022 | 2.78 | Rs 27.5 bn | 1.18% | — |
Sales and profit after tax by quarter, Rs billion
Sales, Rs bn
Profit after tax, Rs bn
Method
A blank is a quarter not filed separately. The fourth quarter is filed only inside the annual accounts.| Quarter | Earnings per share (Rs) | Sales | Profit after tax | Change on the same quarter a year before |
|---|---|---|---|---|
| Quarter to 30 Sep 2026 | 13.05 | Rs 10.0 bn | Rs 1.5 bn | -5.4% |
| Quarter to 30 Jun 2026 | 14.32 | Rs 10.1 bn | Rs 1.7 bn | +3.2% |
| Quarter to 31 Mar 2026 | 13.03 | Rs 9.6 bn | Rs 1.5 bn | — |
| Quarter to 30 Sep 2025 | 13.80 | Rs 10.6 bn | Rs 1.6 bn | — |
| Quarter to 30 Jun 2025 | 13.87 | Rs 11.6 bn | Rs 1.6 bn | — |
Company accounts as filed. Earnings per share are on today’s share count where a split or bonus issue came later. Years to 31 December. 4 of the last 5 years and 5 of the last 8 quarters.
Next results
Full-year results, to 31 Dec 2026: expected between 7 Feb 2027 and 31 Mar 2027.
A projection, not an announced date. An estimate from the dates of the last 4 filings.
Annual figures from the accounts filed with PSX. Amounts in rupees; earnings per share (EPS) in rupees a share.
| FY (December) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales | Rs 43.1B | Rs 37.2B | Rs 31.6B | Rs 27.5B |
| Profit after Taxation | Rs 6.4B | Rs 4.6B | Rs 996M | Rs 325M |
| EPS | Rs 54.45 | Rs 39.11 | Rs 8.51 | Rs 2.78 |
| EPS Growth | +39.2% | +359.6% | +206.1% | −84.8% |
| Gross Profit Margin | 39.1% | 34.5% | 20.4% | 17.4% |
| Net Profit Margin | 14.8% | 12.3% | 3.1% | 1.2% |
05AccountsCash, debt and the balance sheet
Where the cash came from and went
| Profit after tax | Rs 6.4 bn |
| Operating cash flow | Rs 5.6 bn |
| Dividends paid | −Rs 3.5 bn |
| Change in cash | Rs 378.6 m |
| Cash at the start of the year | Rs 6.8 bn |
| Cash at the end of the year | Rs 7.2 bn |
Accounts, year to 31 Dec 2025 · filed annual report, page 41The report does not say whether these are group accounts or the company’s own.
Borrowings and cash
Interest covered by operating profit: Rs 10.7 bn against Rs 22.4 m, 477.1 times
Accounts, year to 31 Dec 2025 · filed annual report, page 41The report does not say whether these are group accounts or the company’s own.
Ratios from the filed accounts
| Interest covered by operating profit | 477.1 times |
| Cash earned for each rupee of profitoperating cash flow over profit after tax | Rs 0.88 |
| Change in earnings per share on the year before | +39.2% |
| Price per rupee earned, our owncompany accounts, twelve months to 31 Dec 2025 | 12.63 |
The other rows: accounts, year to 31 Dec 2025 · filed annual report, page 41The report does not say whether these are group accounts or the company’s own.
Yes-or-no tests on the accounts
Year to 31 Dec 2025 against year to 31 Dec 2024.
Met and not met
| Profit after tax above zerothis year Rs 6.4 bn | met |
| Operating cash flow above zerothis year Rs 5.6 bn | met |
| Operating cash flow above profit after taxthis year Rs 5.6 bn, profit after tax Rs 6.4 bn | not met |
| Gross profit as a share of sales rosethis year 39.1%, year before 34.5% | met |
4 of the 9 tests are shown. The other tests cannot be worked out from the accounts shown here, so no total is given.
Accounts, year to 31 Dec 2025 · filed annual report, page 41The report does not say whether these are group accounts or the company’s own.
Balance sheet and returns
Haleon Pakistan balance sheet and returns
Return on equity, book value, gearing and margins for Haleon Pakistan, from the company’s own audited annual report. Figures for the year ended 31 Dec 2025, 11 months old.
- Book value / share
- Rs 126.41
- Price to book
Price to book
What the market charges for each rupee of net assets.
How it's worked out
Share price divided by book value per share.
How to read it
Under 1 means the market values the whole company at less than the net assets on its own balance sheet. On PSX that is common and is sometimes a bargain and sometimes a warning — check why.
- 5.44×
- Current ratio
Current ratio
Can it pay the bills due inside a year?
How it's worked out
Current assets divided by current liabilities, from the annual report.
How to read it
Under 1 means more falls due within a year than the company expects to collect within one. Not fatal on its own — but it is the first place to look when a company is in trouble.
- 1.57×
- Liabilities to equity
Liabilities to equity
How much is owed against how much is owned outright.
How it's worked out
Total liabilities divided by total equity. The broad measure — all liabilities, not only interest-bearing borrowings — because that is what the published tables reliably carry.
How to read it
Leverage magnifies both directions. High gearing is normal for banks and leasing, alarming for a manufacturer in a high-rate year like Pakistan has had.
- 0.84×
- Funded by shareholders
Funded by shareholders
The share of the balance sheet shareholders actually paid for.
How it's worked out
Total equity as a percentage of total assets — the plain-English complement of leverage.
How to read it
The higher it is, the less the company depends on lenders staying friendly. At Pakistani interest rates that dependence has cost a great deal.
- 55%
| Year ended | Total assets | Equity | Revenue | Profit | Return on equity |
|---|---|---|---|---|---|
| 31 Dec 2025accounts not labelled | Rs 27.2B | Rs 14.8B | Rs 43.1B | — | — |
| 31 Dec 2024accounts not labelled | Rs 21.8B | Rs 12B | Rs 37.2B | — | — |
| 31 Dec 2023accounts not labelled | Rs 18.2B | Rs 8B | Rs 31.6B | Rs 996M | 12.4% |
| 31 Dec 2022accounts not labelled | Rs 15.1B | Rs 7B | Rs 27.5B | Rs 325M | 4.6% |
| 31 Dec 2021accounts not labelled | Rs 13.9B | Rs 6.7B | Rs 24.2B | Rs 2.1B | 31.8% |
Source: Haleon Pakistan’s annual report, page 41. Every figure above can be checked against it.
06DividendsRs 25.00 a share, 12 months
Every payout
What dividends has HALEON paid?
PSX quotes payouts as a % of the Rs 10 face value — 25% = Rs 2.50 per share. Unconfirmed ex-dates are marked “expected”.
Dividends, by financial year
Cash dividends, counted in the financial year of the ex-dividend date. Twelve months from 20 Nov 2025: Rs 25.00 a share.
Dividends paid a share by financial year, with the yield at each year end
Paid a share, Rs
Yield at year end
Method
Bars: paid a share on today's share basis, after splits and bonus issues. Yield: the year's dividends over the last close on or before the year end. A year with no yield shows no point. * The year in progress. Source: PSX payout notices and closes.| Financial year | Paid a share | Payouts | Yield at year end |
|---|---|---|---|
| Year to 31 Dec 2026 (year in progress) | Rs 25.00 | 2 | — |
| Year to 31 Dec 2025 | Rs 30.00 | 3 | 3.60% |
| Year to 31 Dec 2024 | Rs 5.00 | 1 | 0.62% |
Source: PSX payout notices.
| Type | % of face | Per share | Ex-date | Book closure | Qualify by |
|---|---|---|---|---|---|
| Cash dividend | 100% | Rs 10.00 | 7 Sep 2026 | 8 Sep 2026 – 9 Sep 2026 | 4 Sep 2026 |
| Cash dividend | 150% | Rs 15.00 | 21 Apr 2026 | 22 Apr 2026 – 28 Apr 2026 | 20 Apr 2026 |
| Cash dividend | 50% | Rs 5.00 | 4 Nov 2025 | 6 Nov 2025 – 7 Nov 2025 | 3 Nov 2025 |
No matches.
07Peers6 companies
Peers table
Other Pharmaceuticals stocks on PSX
Other companies in the same PSX sector, including its largest.
Against the largest companies in its sector
Price per rupee earned
Sector median 12.32×
Dividend yield, payers only
Sector median 5.12%
Net profit as a share of sales
Sector median 9.4%
Price change over 1 year
Market value, Rs billion
The company and the largest 5 others in its sector by market value, as of 20 Nov 2026. Sources: PSX prices and filed accounts.
| Symbol | Company | Price | Chg % | Mkt cap | Price/earnings |
|---|---|---|---|---|---|
| HINOON | Highnoon Laboratories Limited | 976.84 | +1.74% | Rs 51.8B | 12.6× |
| HPL | Hoechst Pakistan Limited | 4,000.00 | 0.00% | Rs 38.6B | 11.0× |
| IBLHL | IBL HealthCare Limited | 41.58 | −0.72% | Rs 4.1B | 19.1× |
| GLAXO | GlaxoSmithKline Pakistan Limited | 332.02 | −0.92% | Rs 106B | 9.6× |
| ABOT | Abbott Laboratories (Pakistan) Limited | 1,013.28 | +0.42% | Rs 99.2B | 10.7× |
| SEARL | The Searle Company Limited | 79.69 | +0.18% | Rs 46.9B | 12.1× |
No matches.
6 of 6 companies shown have a price-to-earnings ratio in Pharmaceuticals; a blank cell means a loss or no ratio. Each ratio is the one printed on that company’s own page, to 20 Nov 2026.
08Price position11% of the 52-week range
Where the price stands
Closing price over one year
Close52-week low52-week high
Rs 652.50 · 2 turns · last 2 Nov 2026Rs 737.77 · 3 turns · last 9 Oct 2026
Method
The 52-week low 650.00 and high 1,010.00 are intraday highs and lows, set 2 Nov 2026 and 9 Jan 2026. Source: PSX closes.Closing price over the last 20 sessions
Levels where the price turned most often in the last 12 months, one below and one above the close on 20 Nov 2026. A turn is a daily high or low that is the highest or lowest of the 5 sessions before it and the 5 after it; turns close together count as one level. Each line runs from its first turn to its last and stops there. Prices from 21 Nov 2025 to 20 Nov 2026, 248 sessions, adjusted for splits and bonus issues. Source: PSX daily prices.
- Rs 652.50, below the close on 20 Nov 2026: 2 turns, the first on 7 Apr 2026 and the last on 2 Nov 2026.
- Rs 737.77, above the close on 20 Nov 2026: 3 turns, the first on 8 Jun 2026 and the last on 9 Oct 2026.
Dated events on the one-year chart, 20 Nov 2025 to 20 Nov 2026, newest first: R results filed, D ex-dividend, B bonus issue, S split, T dealing by a director or major owner. Marked: dividend, bonus and split dates in the window, the latest results filing and the latest dealings. A number marks that many events too close together to draw apart. Sources: the company’s notices to PSX and the exchange’s payout records.
- R 29 Oct 2026 · Results filed: Nine-month results, to 30 Sep 2026
- D 7 Sep 2026 · Ex-dividend: Rs 10.00 a share
- D 21 Apr 2026 · Ex-dividend: Rs 15.00 a share
Place in the 52-week range
- Place in the 52-week range
- 10.5% of the way from the low to the highintraday highs and lows, as of 20 Nov 2026
Reading of the last 14 days, weeks and months
- Reading of the last 14 sessions
- 53.7 on a scale of 0 to 100, between 30 and 70session of 20 Nov 2026; below 30 and above 70 mark the two outer bands
- Week reading, 14 weeks
- 40.4 on a scale of 0 to 100week to 20 Nov 2026; close Rs 687.73, level with the average of the last 10 weekly closes, Rs 683.83; level means within 1% of the average
- Month reading, 14 months
- 53.0 on a scale of 0 to 100month to 30 Oct 2026; close Rs 658.80, below the average of the last 10 monthly closes, Rs 764.52
Trend strength, 14 sessions
- Trend strength, 14 sessions
- 29.6 on a scale of 0 to 100over 14 daily sessions
- Volume
- 7,304, 0.3 times the average of the 30 sessions before it, 27,781Average of the 30 sessions before the last.
PSX daily closes, as of 20 Nov 2026.
Trend and technical readings
Trend read
Sideways
Since 5 Nov 2026 · daily closes to 20 Nov 2026
- •Above the 50-day average, below the 200-day
- •Roughly flat over 3 months (−5.8%)
A description of the price series — moving averages, momentum, the 52-week position — held for three closes before it changes. It is a label, not advice. How it works
- Buying vs selling, 14 sessions
Buying vs selling, 14 sessions
Whether recent buying or selling has run hot.
How it's worked out
Fourteen sessions of gains weighed against losses, on a 0–100 scale.
How to read it
Above 70 is called overbought and below 30 oversold. A share that keeps rising can sit above 70 for months, so this describes what the price has done; it does not forecast a turn.
- 54
- neutral band
- vs 50-day avg
- +0.8%
- SMA Rs 682.06
- vs 200-day avg
- −8.4%
- SMA Rs 751.16
- Beta vs KSE-100
Beta
How hard it swings when the market swings.
How it's worked out
The slope of this stock's daily returns against the KSE-100's, over a year of sessions.
How to read it
1.0 moves with the market, 1.5 exaggerates it by half, below 1 is steadier. It says nothing about direction, only about size.
- 0.86
- correlation 0.77 · 1Y
- Volatility
Volatility, 30-day
How jumpy it has been lately, stated per year.
How it's worked out
The standard deviation of the last 30 days of returns, annualised.
How to read it
30% means a typical year's swing of about thirty percent either way. Rising volatility often arrives before news does.
- 17%
- 30d · 15% 90d, annualised
- Max drawdown · 1Y
Biggest drawdown
The worst peak-to-trough fall of the last year.
How it's worked out
The largest drop from any high to any subsequent low over 250 sessions.
How to read it
The number that tells you whether you could have held it. Most people discover their real risk tolerance somewhere inside this figure.
- −34.2%
- Volume vs 20-day avg
Volume vs normal
How busy today was against a typical day.
How it's worked out
The latest session's volume divided by the twenty-day average.
How to read it
Above 2 means something happened — an announcement, a block, a rumour. Check the news before reading anything into the price.
- 0.23×
- 20-session average 30,986
- 52-week signal
Position in 52-week range
Where today's price sits between the year's low and high.
How it's worked out
Zero at the 52-week low, 100 at the high.
How to read it
Near 100 is strength or froth; near 0 is a bargain or a falling knife. The number tells you where you are, never which of the two.
- Inside range
Figures as of 20 Nov 2026, from daily closes.
09OwnersWho owns the shares
Who holds the shares
- Free float
- 13.4% of sharesas of 30 Oct 2026
- Held in the central depository, other than by the government
- 13.4%as of 30 Nov 2025
Source: SuperX ownership data · free float as of 30 Oct 2026, custody file of 30 Nov 2025.
About the company
About Haleon Pakistan Limited
Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited) was incorporated in Pakistan as a public listed company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017) on 31 March 2015. The Company is a subsidiary of ‘Haleon Netherlands B.V’. The ultimate parent of the Company is Haleon plc. The Company is inter alia principally engaged in the manufacturing, marketing and sale of consumer healthcare and over the counter health products.
Key people
- Qawi Naseer · CEO
- Farhan Muhammad Haroon · Chairperson
- Mashal Mohammad · Company Secretary
- Sector
- Pharmaceuticals
- Website
- www.haleon.pk
- Head office
- 11-A, 11th Floor, Sky Tower (East Wing), Dolmen City, HC-3, Block 4, Scheme-5, Clifton, Karachi, 75600
- Auditor
- M/s KPMG Taseer Hadi & Co. Chartered Accountants
- Share registrar
- CDC Share Registrar Services Limited CDC House, Main Shahrah-e-Faisal, Karachi.
- Fiscal year end
- December
10Dated record49 dated events
What matters now for HALEON
Three dates that matter, as of 20 Nov 2026.
-
Last ex-dividend
7 Sep 2026
Rs 10.00 a share
the first day a buyer gets no dividend. 74 days before 20 Nov 2026.
-
Next results
7 Feb 2027
Full-year results expected between 7 Feb 2027 and 31 Mar 2027
projected — An estimate from this company’s own past filing dates. Not a date the company gave. 79 days after 20 Nov 2026.
-
Last large move
14 Jul 2026
-3.27%
HALEON closed down 3.3% at Rs 758.20. This was a sector day. 13 of 15 PHARMACEUTICALS stocks fell. The typical one fell 3.6%. 50,076 shares traded, 0.6 times a normal day. HALEON filed nothing that moves a price, that session or the day before.
The dated record
HALEON’s dated record
The exchange’s own record and ours: ex-dividends, book closures, results, every session move of 3% or more with the reason written out, the notices that move a price, and the news about Haleon Pakistan. Dates that have not happened are kept apart from dates that have, and each one says whether it was announced or projected.
Ahead · 1
These dates are after 20 Nov 2026. None of them has happened. A row marked projected is an estimate from the company’s past filing dates; a row marked announced is a date on the exchange’s record.
- 7 Feb 2027 Results Full-year results expected between 7 Feb 2027 and 31 Mar 2027 projected — An estimate from this company’s own past filing dates. Not a date the company gave.
The last 90 days · 6
-
29 Oct 2026
- Notice Financial results Financial Results for the Quarter Ended 30 September 2026
- Results Nine-month results, to 30 Sep 2026
same day, order not known
-
21 Oct 2026
- Notice Board meeting Notice of Board of Directors Meeting - (Q3-2026)
-
7 Sep 2026
- Ex-dividend Rs 10.00 a share
-
27 Aug 2026
- Notice Financial results Financial Results for the Quarter Ended 30 June 2026
Earlier · 42
Move 20 session moves, 28 Oct 2025 to 14 Jul 2026 open
- 14 Jul 2026 -3.27% HALEON closed down 3.3% at Rs 758.20. This was a sector day. 13 of 15 PHARMACEUTICALS stocks fell. The typical one fell 3.6%. 50,076 shares traded, 0.6 times a normal day. HALEON filed nothing that moves a price, that session or the day before.
- 15 Jun 2026 +4.94% HALEON closed up 4.9% at Rs 811.30. This was a sector day. 13 of 14 PHARMACEUTICALS stocks rose. The typical one rose 3.8%. 324,217 shares traded, 7.0 times a normal day. HALEON filed nothing that moves a price, that session or the day before.
- 1 Jun 2026 -3.04% HALEON closed down 3.0% at Rs 759.92. Its sector's typical stock fell 0.9%; the KSE-100 fell 1.9%. So this was HALEON's own move. 43,862 shares traded, 0.6 times a normal day. HALEON filed nothing that moves a price, that session or the day before.
- 21 May 2026 +3.51% Up 3.5% on 0.8× the usual volume. The pharmaceuticals sector moved the same way, median +1.8% (12 of 15 names up). The KSE-100 moved +2.2% the same day. Foreign investors were net sellers of Rs 1,599M across the market.
- 6 May 2026 +4.74% Up 4.7% on 0.5× the usual volume. The pharmaceuticals sector moved the same way, median +3.4% (14 of 14 names up). The KSE-100 moved +4.2% the same day.
- 17 Apr 2026 +6.75% Up 6.7% on 1.9× the usual volume. The pharmaceuticals sector moved the same way, median +3.5% (13 of 15 names up). The KSE-100 moved +2.4% the same day.
- 14 Apr 2026 +3.67% Up 3.7% on 0.6× the usual volume. The pharmaceuticals sector moved the same way, median +4.0% (14 of 14 names up). The KSE-100 moved +3.1% the same day.
- 13 Apr 2026 -4.03% Down 4.0% on 0.6× the usual volume. The pharmaceuticals sector moved the same way, median -4.5% (14 of 14 names down). The KSE-100 moved -3.9% the same day.
- 8 Apr 2026 +10% Up 10.0% on 2.5× the usual volume, gapping 10.0% at the open. The pharmaceuticals sector moved the same way, median +10.0% (15 of 15 names up). The KSE-100 moved +9.3% the same day. Foreign investors were net sellers of Rs 1,793M across the market. Closed at the exchange's daily price limit.
- 26 Mar 2026 -3.53% Down 3.5% on 1.4× the usual volume. The pharmaceuticals sector moved the same way, median -3.1% (14 of 14 names down). The KSE-100 moved -3.4% the same day.
- 10 Mar 2026 +5.48% Up 5.5% on 3.7× the usual volume. The pharmaceuticals sector moved the same way, median +7.9% (14 of 15 names up). The KSE-100 moved +6.6% the same day.
- 9 Mar 2026 -10% Down 10.0% on 3.5× the usual volume, gapping 3.3% at the open. The pharmaceuticals sector moved the same way, median -9.6% (14 of 14 names down). The KSE-100 moved -7.0% the same day. Closed at the exchange's daily price limit.
- 2 Mar 2026 -10% Down 10.0% on 3.4× the usual volume, gapping 10.0% at the open. The pharmaceuticals sector moved the same way, median -10.0% (14 of 14 names down). The KSE-100 moved -9.6% the same day. Foreign investors were net sellers of Rs 1,254M across the market. A board meeting was notified within the last two sessions. Closed at the exchange's daily price limit.
- 29 Jan 2026 -3.1% Down 3.1% on 0.8× the usual volume. The pharmaceuticals sector moved the same way, median -2.5% (14 of 15 names down). The KSE-100 moved -3.2% the same day. Foreign investors were net buyers of Rs 1,438M across the market.
- 19 Jan 2026 +4.13% Up 4.1% on 1.1× the usual volume. The KSE-100 moved +1.4% the same day. Foreign investors were net sellers of Rs 1,066M across the market. A new 52-week high.
- 13 Jan 2026 -3.58% Down 3.6% on 2.1× the usual volume.
- 8 Jan 2026 +4.63% Up 4.6% on 6.6× the usual volume. Foreign investors were net sellers of Rs 1,043M across the market. A new 52-week high.
- 7 Jan 2026 +5.62% Up 5.6% on 4.8× the usual volume. The pharmaceuticals sector moved the same way, median +2.0% (15 of 15 names up).
- 1 Jan 2026 +5.59% Up 5.6% on 4.5× the usual volume. The pharmaceuticals sector moved the same way, median +2.2% (13 of 15 names up). The KSE-100 moved +1.3% the same day.
- 28 Oct 2025 -3.06% Down 3.1% on 0.9× the usual volume. The KSE-100 moved -1.3% the same day. Financial results were announced within the last two sessions.
Notice 17 notices, 16 Oct 2024 to 20 Aug 2026 open
- 20 Aug 2026 Board meeting Notice of Board of Directors Meeting - (Q2-2026)
- 29 Apr 2026 Financial results Financial Results for the Quarter Ended 31 March 2026
- 20 Apr 2026 Board meeting Notice of Board of Directors Meeting - (Q1-2026)
- 3 Mar 2026 Financial results Financial Results for the Year Ended 31 December 2025
- 2 Mar 2026 Board meeting Board Meeting In Progress
- 23 Feb 2026 Board meeting Notice of Board of Directors Meeting - (Q4-2025)
- 27 Oct 2025 Financial results Financial Results for the Quarter Ended 30 September 2025
- 20 Oct 2025 Board meeting Notice of Board of Directors Meeting - (Q3-2025)
- 26 Aug 2025 Financial results Financial Results for the Quarter Ended 30 June 2025
- 18 Aug 2025 Board meeting Notice of Board of Directors Meeting - (Q2-2025)
- 28 Apr 2025 Financial results Financial Results for the Quarter Ended 31 March 2025
- 18 Apr 2025 Board meeting Notice of Board of Directors Meeting - (Q1-2025)
- 7 Feb 2025 Financial results Additional Information to Financial Results for the Year Ended 31 December 2024
- 6 Feb 2025 Financial results Financial Results for the Year Ended 31 December 2024
- 29 Jan 2025 Board meeting Notice of Board of Directors Meeting - (Q4-2024)
- 24 Oct 2024 Financial results Financial Results for the Period Ended 30 September 2024
- 16 Oct 2024 Board meeting Notice of Board of Directors Meeting - (Q3-2024)
Ex-dividend 5 ex-dividends, 5 Nov 2024 to 21 Apr 2026 open
- 21 Apr 2026 Rs 15.00 a share
- 4 Nov 2025 Rs 5.00 a share
- 2 Sep 2025 Rs 10.00 a share
- 11 Mar 2025 Rs 15.00 a share
- 5 Nov 2024 Rs 5.00 a share
Showing the most recent session moves and notices. Every ex-dividend, book closure, results filing and ticker change is listed.
Announcements on PSX
What has Haleon Pakistan announced on PSX?
The latest 5 notices Haleon Pakistan filed with the exchange, newest first. The title is the exchange’s own text, as filed. The PDF opens at PSX.
- 12 Nov 2026 · Restructuring Change of Name of External Auditors PDF on PSX
- 30 Oct 2026 · Report sent to shareholders Transmission of Quarterly Report for the Period Ended 30 September 2026 PDF on PSX
- 30 Oct 2026 · Material information Disclosure of Material Information PDF on PSX
- 29 Oct 2026 · Financial results Financial Results for the Quarter Ended 30 September 2026 PDF on PSX
- 21 Oct 2026 · Board meeting Notice of Board of Directors Meeting - (Q3-2026) PDF on PSX
From the company’s announcements on the Pakistan Stock Exchange (dps.psx.com.pk), read 21 Nov 2026.
Dates and events on this page are read as of 20 Nov 2026.
11QuestionsQuick answers
HALEON share price: quick answers
What is the Haleon Pakistan (HALEON) share price?
As of 20 Nov 2026, the Haleon Pakistan (HALEON) share price is Rs 687.73 (0.00% on the day). Over the last year it has moved −16.25%.
What was HALEON's last dividend?
Its last cash dividend was Rs 10.00 a share, ex-date 7 Sep 2026.
What is HALEON's dividend yield?
As of 20 Nov 2026, Haleon Pakistan Limited (HALEON) has a trailing dividend yield of 3.64% at a share price of Rs 687.73. Cash dividends declared over the last 12 months total Rs 25.00 per share.
How much does HALEON cost for each rupee it earns?
At Rs 687.73 a share on 20 Nov 2026, each rupee HALEON earned over the last twelve months costs Rs 12.35. That is a trailing price-to-earnings ratio of 12.35×. Its market capitalisation is about Rs 80.5B.
Is HALEON Shariah compliant?
Yes. PSX lists Haleon Pakistan Limited (HALEON) as Shariah-compliant as of 20 Nov 2026 and is included in the KMI All-Share Islamic index. Screening status can change at each review, so confirm with your Shariah advisor before investing.
Is HALEON trending up or down?
SuperX's trend read for HALEON is Sideways since 5 Nov 2026: the price series is roughly flat. Above the 50-day average, below the 200-day; Roughly flat over 3 months (−5.8%). The read describes the closes through 20 Nov 2026; it is not a recommendation.
What does HALEON cost against what it earns?
HALEON shows an earnings yield of 8.10%, a payout ratio of 46%, a net margin of 14.8%. Its price-to-earnings multiple is lower than 50% of companies in the same PSX sector with reported earnings. Whether that price is low or high depends on why the market sets it there, which no ratio answers. A Rs 1,000,000 order is about 8% of a normal session, judged on the median value traded over the last 60 sessions.
What is the total return on HALEON including dividends?
HALEON returned -13.2% over the last year counting the cash dividends paid, against a price move of -16.2% — a gap of 3.0 percentage points that a price chart alone hides. Dividends are counted as received on their ex-date, not reinvested. Figures to 20 Nov 2026.
How liquid is HALEON?
On SuperX's reading of the last 60 sessions, a Rs 1,000,000 order moves the price about 5 basis points on a median session, the implied bid-ask spread works out at about 0.92% of price, the stock traded on 100% of the last year's sessions. Those are estimates from daily closes and volumes, not from the order book, and they describe normal sessions rather than the one session an order has to clear.
What is HALEON's beta?
HALEON's one-year beta against the KSE-100 is 0.86 (correlation 0.77), measured on daily closes to 20 Nov 2026. Its annualised volatility is 17% over 30 days and 15% over 90; the worst peak-to-trough fall in the last year was −34.2%.
Was HALEON previously GSKCH?
Before 31 Jan 2023 this company traded as GSKCH, GlaxoSmithKline Consumer Healthcare. Sessions before that date were recorded under GSKCH. The exchange's filing: “Approval of Company Name Change - Haleon Pakistan Limited”. The chart on this page and the plotter at /chart/HALEON/ draw both tickers as one line; the date of the join is stated beside the plotter.
Who is the CEO of Haleon Pakistan?
The CEO of Haleon Pakistan (HALEON) is Qawi Naseer (PSX company page, 30 Oct 2026).
Who is the chairperson of Haleon Pakistan?
The Chairperson of Haleon Pakistan (HALEON) is Farhan Muhammad Haroon (PSX company page, 30 Oct 2026).
Where is the head office of Haleon Pakistan?
The head office of Haleon Pakistan (HALEON) is at 11-A, 11th Floor, Sky Tower (East Wing), Dolmen City, HC-3, Block 4, Scheme-5, Clifton, Karachi, 75600 (PSX company page, 30 Oct 2026).
Who is the auditor of Haleon Pakistan?
The auditor of Haleon Pakistan (HALEON) is M/s KPMG Taseer Hadi & Co. Chartered Accountants (PSX company page, 30 Oct 2026).
Who is the share registrar of Haleon Pakistan?
The share registrar of Haleon Pakistan (HALEON) is CDC Share Registrar Services Limited CDC House, Main Shahrah-e-Faisal, Karachi (PSX company page, 30 Oct 2026).
When does the financial year of Haleon Pakistan end?
The financial year of Haleon Pakistan (HALEON) ends in December (PSX company page, 30 Oct 2026).
How many shares of Haleon Pakistan are outstanding?
Haleon Pakistan (HALEON) has 117,054,508 shares outstanding (PSX company page, 30 Oct 2026).
What is the free float of Haleon Pakistan?
The free float of Haleon Pakistan (HALEON) is 13.4% of its shares (PSX company page, 30 Oct 2026).
Which PSX indices include Haleon Pakistan?
As of 20 Nov 2026, PSX index data lists Haleon Pakistan (HALEON) in the All-Share, KMI All-Share and KSE-100 indices and 1 other PSX index.
What does Haleon Pakistan do?
The company profile on PSX (30 Oct 2026) reads: Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited) was incorporated in Pakistan as a public listed company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017) on 31 March 2015. The Company is a subsidiary of ‘Haleon Netherlands B.V’.
Answers use the facts on this page. Prices are as of 20 Nov 2026.
12SourcesGuides, filings and sources
Guides for HALEON
Plain explanations of the figures on this page.
Filings and reports
Haleon Pakistan filings and reports
28 documents Haleon Pakistan has published — annual reports, quarterly accounts and briefing decks. PSX filings are marked PSX; the rest come from the company’s own investor relations page (visit it). Links open the original PDF at the source.
Annual reports · 13
- Annual report 2025 PSX
- Annual report 2024 Company
- Annual report 2023 Company
- Annual report 2022 Company
- gskch annual report 2017 Company
- haleon annual report 2025 Company
- annual report 2024 haleon pakistan limited Company
- haleon annual report 2023 Company
and 5 more
Quarterly accounts · 15
- Transmission of Quarterly Report for the Period Ended 30 September 2026 PSX
- Financial Results for the Quarter Ended 30 September 2026 PSX
- Quarterly report 2026 PSX
- Financial Results for the Quarter Ended 30 June 2026 PSX
- Financial Results for the Quarter Ended 31 March 2026 PSX
- Quarterly report 2026 PSX
- Quarterly report 2025 Company
- Quarterly report 2025 Company
and 7 more
Sources and dates
| Figures | Source | As of |
|---|---|---|
| Returns | PSX daily closes, KSE-100 closes | 20 Nov 2026 |
| Dividends | PSX payout notices, bonus and rights records | 18 Nov 2026 |
| Results | Accounts filed with PSX | 30 Sep 2026 |
| Cash flow, Borrowings and cash, Ratios, Tests on the accounts | The filed annual report | 31 Dec 2025 |
Each row’s date is the latest one its figures stand at.
Data from PSX via SuperX, delayed and provided for information only — not investment advice. Figures may contain errors; verify with your broker before acting. As of .
Track HALEON in your portfolio, from 23 December
Trade logging, price alerts and smart-money flows for PSX investors. Join the waitlist and we email once, when it is ready.
SuperX is not a broker and not an adviser. It never places an order and never asks for a broker login.